On Wednesday, Novo Nordisk A/S (NYSE:NVO) reported third-quarter 2024 sales of 71.311 billion Danish kroner (around $10.3 billion), missing the consensus of 71.89 billion Danish kroner. The global sales increased 21% year over year (up 23% at constant currency), driven by increased sales across the portfolio. GLP-1 diabetes sales increased by 15% at CER to […]

Novo Nordisk A/S’s (NYSE:NVO) shared data Friday on its kidney outcomes trial, FLOW. The trial evaluated once-weekly injectable Ozempic for the treatment of type 2 diabetes. The FLOW (Evaluate Renal Function with Semaglutide Once Weekly) study included 3,533 patients with a median follow-up period of 3.4 years. In March, the company released headline data demonstrating a 24% reduction […]

AstraZeneca plc (NASDAQ:AZN) reported topline data from a metastatic breast cancer treatment study. The results showed that Enhertu (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy in the primary trial population of patients with HR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer following one or more lines of endocrine […]

On Monday, Palatin Technologies Inc. (NYSE:PTN) announced the presentation of topline results for its Phase 3 PL9643 MELODY-1 trial, which evaluated the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease (DED) at the American Society of Cataract and Refractive Surgery. The company released the mixed topline data in February 2024. The presentation included […]